Adicet Bio (ACET) AI Stock Analysis

• Market Cap: $68.81M
• Dividend Yield: N/A
• Average Volume (3M): 1.92M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.52
• Revenue Growth: N/A
• EPS Growth: 25.89%
• Country: US
• Employees: 152
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -2.94
• Shares Outstanding: 9,596,407
• 10 Day Avg. Volume: 4,877,229
• 30 Day Avg. Volume: 1,918,806
• PEG Ratio: 0.02
• Price to Book (P/B): 0.36
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.60
• Enterprise Value/Market Cap: 0.65
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -30.31
• Enterprise Value/Ebitda: -0.39
• 1Y Price Target: $42.60
• Price Target Upside: 494.14% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): -33.73
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $7.00 ▼(-2.37% Downside)
• Action: Reiterated Date: 03/13/26
• Date: Action: Reiterated 03/13/26

The score is primarily constrained by weak financial performance (no revenue, large losses, and substantial ongoing cash burn) and bearish technical positioning (below major moving averages with negative MACD). These are partially offset by a supportive low-debt balance sheet and a positive corporate update that includes trial momentum, FDA alignment, and extended runway into 2H 2027.

Positive Factors

Cash runway

A cash balance of $158.5M plus an October 2025 $74.8M equity raise that management says funds operations into H2 2027 materially lowers near-term financing urgency. This gives management time to deliver 2026 clinical and regulatory milestones and reduces immediate execution risk while programs mature.

Clinical progress & FDA alignment

Enrollment momentum across autoimmune cohorts and FDA alignment for outpatient dosing are structural positives: they de-risk trial logistics, expand potential patient access, lower per-patient costs, and support a pathway toward pivotal design and regulatory interactions, enhancing program credibility over the medium term.

Low financial leverage

Very low debt reduces solvency and interest-rate pressure, preserving cash for R&D and trials. This structural balance-sheet strength provides financial flexibility through development cycles, limiting forced distressed financing and giving management options to prioritize clinical execution over near-term debt servicing.

Negative Factors

High cash burn

Sustained operating and free cash outflows near $95–97M annually create a structural dependence on external capital. Even with current runway, ongoing high burn increases dilution and execution risk if financing windows close, and forces trade-offs between programs if funding is constrained over the next 2–6 months.

No recurring revenue

Absence of product revenue means the business cannot self-fund development or offset fixed costs; valuation and survival hinge entirely on R&D progress, partnerships, or capital markets. This structural reliance on external funding persists until commercialization, limiting margin stability and long-term resilience.

Equity erosion & dilution risk

Material decline in equity over several years signals cumulative losses and likely past dilution. Combined with recent equity raises and a securities shelf, this erosion reduces the company’s buffer against shocks, raises future dilution odds, and constrains long-term investor protection absent successful clinical outcomes.

Adicet Bio Business Overview & Revenue Model

Company Description

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.

How the Company Makes Money

As a clinical-stage biotechnology company, Adicet Bio does not have publicly established, recurring product revenue from marketed therapies (null). Its cash inflows have historically been driven primarily by (1) collaboration and partnership-related revenue, such as upfront payments, research funding, and potential milestone payments tied to development, regulatory, or commercial events under strategic agreements (specific partner terms and current-period amounts: null), and (2) financing activities, principally raising capital through issuing equity and related instruments (amounts and timing: null). The company may also earn interest income on cash and investments (materiality: null). Until it successfully commercializes a therapy, its ability to generate revenue is largely dependent on securing and maintaining partnership arrangements and accessing capital markets to fund R&D and clinical development.

Adicet Bio Financial Statement Overview

Summary

Income statement and cash flow remain weak due to no recent revenue and large ongoing losses with heavy negative operating/free cash flow (2025 OCF about -$95.2M; FCF about -$97.0M). Balance sheet leverage is low (debt-to-equity ~0.09), but equity has eroded materially over time, reflecting sustained burn.

Income Statement

ACET remains a pre-commercial biotech profile with no revenue in 2023–2025 (annual), following modest revenue in 2020–2022. Losses are large but have improved versus 2023: EBIT moved from -$152.0M (2023) to -$127.6M (2024) and -$122.1M (2025), with net loss also improving to -$116.8M (2025) from -$142.7M (2023). The key weakness is the lack of a current revenue base to absorb operating expenses, keeping profitability deeply negative despite some cost discipline.

Balance Sheet

The balance sheet is supported by low leverage, with debt-to-equity around ~0.09 in 2024–2025 and total debt of ~$14.7M against ~$159.2M of equity in 2025. However, the equity base has declined materially since 2021–2022 (from ~$303.1M in 2021 and ~$292.3M in 2022 to ~$159.2M in 2025), reflecting ongoing losses and cash burn; returns on equity are sharply negative (about -73% in 2025). Overall, solvency risk from debt looks limited, but balance-sheet erosion remains a clear concern.

Cash Flow

Cash generation is weak with consistently negative operating cash flow and free cash flow. In 2025, operating cash flow was about -$95.2M and free cash flow about -$97.0M, and free cash flow deteriorated sharply versus 2024 (free cash flow growth around -3.37). A partial positive is that cash burn is broadly in line with reported losses (free cash flow roughly matches net loss across years), but the scale and persistence of outflows indicate continued reliance on external funding to sustain operations.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	24.99M	9.73M
Gross Profit	-6.38M	0.00	0.00	24.99M	9.73M
EBITDA	-115.73M	-110.65M	-136.53M	-64.70M	-60.41M
Net Income	-116.80M	-117.12M	-142.66M	-69.79M	-62.00M
Balance Sheet
Total Assets	192.35M	220.22M	207.29M	330.69M	338.94M
Cash, Cash Equivalents and Short-Term Investments	38.92M	176.30M	159.71M	257.66M	277.54M
Total Debt	14.74M	17.23M	20.92M	21.02M	20.94M
Total Liabilities	33.15M	33.61M	37.12M	38.35M	35.81M
Stockholders Equity	159.21M	186.61M	170.18M	292.34M	303.13M
Cash Flow
Free Cash Flow	-96.98M	-93.50M	-98.18M	-61.55M	-64.10M
Operating Cash Flow	-95.25M	-92.38M	-93.72M	-44.77M	-51.05M
Investing Cash Flow	2.39M	-119.24M	-4.46M	-16.78M	-2.80M
Financing Cash Flow	75.25M	111.31M	236.00K	41.51M	242.69M

Adicet Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.17
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACET, the sentiment is Negative. The current price of 7.17 is below the 20-day moving average (MA) of 7.28, below the 50-day MA of 7.64, and below the 200-day MA of 10.48, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 46.05 is Neutral, neither overbought nor oversold. The STOCH value of 26.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACET.

Adicet Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PMVP	53 Neutral	$83.19M	-0.84	-59.07%	―	―	-58.47%
STRO	52 Neutral	$384.95M	-0.32	-1810.01%	―	-34.36%	-59.98%
ARTV	52 Neutral	$152.75M	-1.25	-60.22%	―	-100.00%	-17.10%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GANX	46 Neutral	$96.92M	―	-341.33%	―	―	42.29%
ACET	45 Neutral	$68.81M	-0.50	-77.90%	―	―	25.89%

Adicet Bio Corporate Events

Adicet Bio advances prula-cel autoimmune Phase 1 program

On January 7, 2026, Adicet Bio reported that enrollment in its Phase 1 prulacabtagene leucel (prula-cel) program in autoimmune diseases had more than doubled since October to over 20 patients as of December 31, 2025, with all seven autoimmune cohorts now actively enrolling and the first ANCA-associated vasculitis patient dosed. The company has secured U.S. FDA alignment to allow outpatient dosing of lupus nephritis and systemic lupus erythematosus patients in ongoing and future trials, is running a Phase 1 study in treatment-refractory rheumatoid arthritis to test reduced conditioning regimens, and plans multiple clinical data updates through 2026 as it works toward a pivotal trial design. Adicet is also progressing preclinical development of ADI-212 for metastatic castration-resistant prostate cancer, targeting a regulatory filing in the first half of 2026, while an October 2025 equity raise of about $74.8 million has extended its cash runway into the second half of 2027, underpinning its ability to execute on these clinical and regulatory milestones.

The most recent analyst rating on (ACET) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Adicet Bio stock, see the ACET Stock Forecast page.

Adicet Bio Implements Reverse Stock Split to Maintain Listing

On December 19, 2025, Adicet Bio’s shareholders approved, and its board subsequently set, a 1-for-16 reverse stock split of the company’s common stock, which became effective at 12:01 a.m. Eastern Time on December 30, 2025. The move reduces Adicet’s outstanding shares from roughly 153.3 million to about 9.6 million without changing the 300 million authorized share count or the stock’s par value, while proportionally adjusting equity incentive plans, options and warrants; trading on the Nasdaq Capital Market began on a split-adjusted basis under the existing “ACET” ticker on December 30, 2025, with fractional share entitlements settled in cash. By shrinking the share count and boosting the per-share trading price, the reverse split is intended to help Adicet regain compliance with Nasdaq’s minimum bid price requirement and preserve its U.S. listing, a key consideration for existing shareholders and for the company’s future access to capital markets.

The most recent analyst rating on (ACET) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Adicet Bio stock, see the ACET Stock Forecast page.

Adicet Bio Shareholders Approve Flexible Reverse Stock Split

On December 19, 2025, Adicet Bio, Inc. held a Special Meeting of Stockholders at which investors approved an amendment to the company’s Restated Certificate of Incorporation authorizing a reverse stock split of its common shares at a ratio between one-for-five and one-for-thirty, with the exact ratio to be determined at the board’s discretion. The strong approval, with more than 111 million votes in favor and only about 2.8 million against, gave management flexibility to reduce the number of outstanding shares, a step commonly used to support compliance with stock exchange listing standards or improve the perceived value of the stock, and rendered unnecessary a contingent proposal to adjourn the meeting for further proxy solicitation.

The most recent analyst rating on (ACET) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Adicet Bio stock, see the ACET Stock Forecast page.